Articles by Gary R. Lichtenstein

Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection

Henao, Maria Paula; Bewtra, Meenakshi; Osterman, Mark T.; More

Inflammatory Bowel Diseases. 21(10):2262-2271, October 2015.

Impact of JC Virus Antibody Testing in Patients with Crohn's Disease with Loss of Response to Infliximab: A Markov Model

Scott, Frank I.; Osterman, Mark T.; McConnell, Ryan A.; More

Inflammatory Bowel Diseases. 19(12):2625-2633, November 2013.

Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies

Reinisch, Walter; Sandborn, William J.; Rutgeerts, Paul; More

Inflammatory Bowel Diseases. 18(2):201-211, February 2012.

Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior

Lichtenstein, Gary R.; Targan, Stephan R.; Dubinsky, Marla C.; More

Inflammatory Bowel Diseases. 17(12):2488-2496, December 2011.

Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: A clinical review and update

Rubin, David T.; Cruz-Correa, Marcia R.; Gasche, Christoph; More

Inflammatory Bowel Diseases. 14(2):265-274, February 2008.